<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36012622</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>16</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9364</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23169364</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease classified as both a neurodegenerative and neuromuscular disorder. With a complex aetiology and no current cure for ALS, broadening the understanding of disease pathology and therapeutic avenues is required to progress with patient care. Alpha-synuclein (&#x3b1;Syn) is a hallmark for disease in neurodegenerative disorders, such as Parkinson's disease, Lewy body dementia, and multiple system atrophy. A growing body of evidence now suggests that &#x3b1;Syn may also play a pathological role in ALS, with &#x3b1;Syn-positive Lewy bodies co-aggregating alongside known ALS pathogenic proteins, such as <i>SOD1</i> and TDP-43. This review endeavours to capture the scope of literature regarding the aetiology and development of ALS and its commonalities with "synucleinopathy disorders". We will discuss the involvement of &#x3b1;Syn in ALS and motor neuron disease pathology, and the current theories and strategies for therapeutics in ALS treatment, as well as those targeting &#x3b1;Syn for synucleinopathies, with a core focus on small molecule RNA technologies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Bradley</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA 6150, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theunissen</LastName><ForeName>Frances</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA 6150, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastaglia</LastName><ForeName>Francis L</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>The Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA 6150, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akkari</LastName><ForeName>P Anthony</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>The Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA 6150, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Crawley, WA 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurology, Duke University Medical Centre, Duke University, Durham, NC 27708, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Black Swan Pharmaceuticals, Wake Forrest, NC 27587, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flynn</LastName><ForeName>Loren L</ForeName><Initials>LL</Initials><Identifier Source="ORCID">0000-0001-5249-547X</Identifier><AffiliationInfo><Affiliation>The Perron Institute for Neurological and Translational Science, Nedlands, WA 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA 6150, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Crawley, WA 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Black Swan Pharmaceuticals, Wake Forrest, NC 27587, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016631" MajorTopicYN="N">Lewy Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="Y">Lewy Body Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="Y">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080874" MajorTopicYN="Y">Synucleinopathies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">alpha-synuclein</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">synucleinopathies</Keyword></KeywordList><CoiStatement>P.A.A. and L.L.F. are employed by Black Swan Pharmaceuticals and hold patents for AOs targeting <i>TARDBP</i>, <i>FUS</i>, and <i>SOD1</i>.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36012622</ArticleId><ArticleId IdType="pmc">PMC9409035</ArticleId><ArticleId IdType="doi">10.3390/ijms23169364</ArticleId><ArticleId IdType="pii">ijms23169364</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013;14:248&#x2013;264. doi: 10.1038/nrn3430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3430</ArticleId><ArticleId IdType="pubmed">23463272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S., Carr K., Reiley L., Diaz K., Guerra O., Altamirano P.F., Pagani W., Lodin D., Orozco G., Chinea A. A comprehensive review of amyotrophic lateral sclerosis. Surg. Neurol. Int. 2015;6:171. doi: 10.4103/2152-7806.169561.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello V., Francolini M. Neuromuscular junction dismantling in amyotrophic lateral sclerosis. Int. J. Mol. Sci. 2017;18:2092. doi: 10.3390/ijms18102092.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18102092</ArticleId><ArticleId IdType="pmc">PMC5666774</ArticleId><ArticleId IdType="pubmed">28972545</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Logroscino G., Hardiman O., Swingler R., Mitchell D., Beghi E., Traynor B.G., Eurals C. Prognostic factors in ALS: A critical review. Amyotroph. Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur K.C., Calvo A., Price T.R., Geiger J.T., Chio A., Traynor B.J. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat. Commun. 2016;7:12408. doi: 10.1038/ncomms12408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukharsky M.S., Skvortsova V.I., Bachurin S.O., Buchman V.L. In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches. Med. Res. Rev. 2021;41:2804&#x2013;2822. doi: 10.1002/med.21725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21725</ArticleId><ArticleId IdType="pubmed">32815157</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Sayana P., Zhang X., Le W. Genetics of amyotrophic lateral sclerosis: An update. Mol. Neurodegener. 2013;8:28. doi: 10.1186/1750-1326-8-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-28</ArticleId><ArticleId IdType="pmc">PMC3766231</ArticleId><ArticleId IdType="pubmed">23941283</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a J., Bustos R. The genetic diagnosis of neurodegenerative diseases and therapeutic perspectives. Brain Sci. 2018;8:222. doi: 10.3390/brainsci8120222.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci8120222</ArticleId><ArticleId IdType="pmc">PMC6316116</ArticleId><ArticleId IdType="pubmed">30551598</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Chio A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014;17:17&#x2013;23. doi: 10.1038/nn.3584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F., Flynn L.L., Anderton R.S., Mastaglia F., Pytte J., Jiang L., Hodgetts S., Burns D.K., Saunders A., Fletcher S., et al. Structural variants may be a source of missing heritability in sALS. Front. Neurosci. 2020;14:47. doi: 10.3389/fnins.2020.00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00047</ArticleId><ArticleId IdType="pmc">PMC7005198</ArticleId><ArticleId IdType="pubmed">32082115</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M., Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: What do we really know? Nat. Rev. Neurol. 2011;7:603&#x2013;615. doi: 10.1038/nrneurol.2011.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.150</ArticleId><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T., Henderson R.D., Talman P.S., Macdonell R.A., Mathers S., Schultz D.W., Needham M., Zoing M., Vucic S., Kiernan M.C. Motor neurone disease: Progress and challenges. Med. J. Aust. 2017;206:357&#x2013;362. doi: 10.5694/mja16.01063.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja16.01063</ArticleId><ArticleId IdType="pubmed">28446118</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Fang F., Hanby M.F., Leigh P.N., Shaw C.E., Ye W., Rijsdijk F. An estimate of amyotrophic lateral sclerosis heritability using twin data. J. Neurol. Neurosurg. Psychiatry. 2010;81:1324&#x2013;1326. doi: 10.1136/jnnp.2010.207464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.207464</ArticleId><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Visscher P.M. Motor neuron disease: Common genetic variants and the heritability of ALS. Nat. Rev. Neurol. 2014;10:549&#x2013;550. doi: 10.1038/nrneurol.2014.166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.166</ArticleId><ArticleId IdType="pubmed">25201239</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman S.A., Hardiman O., Al-Chalabi A., Chi&#xf3; A., Savelieff M.G., Kiernan M.C., Feldman E.L. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21:465&#x2013;479. doi: 10.1016/S1474-4422(21)00414-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00414-2</ArticleId><ArticleId IdType="pubmed">35334234</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses A. Polyallelic structural variants can provide accurate, highly informative genetic markers focused on diagnosis and therapeutic targets: Accuracy vs. Precision. Clin. Pharm. Therap. 2016;99:169&#x2013;171. doi: 10.1002/cpt.288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.288</ArticleId><ArticleId IdType="pmc">PMC4737274</ArticleId><ArticleId IdType="pubmed">26517180</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuk L., Carson A.R., Scherer S.W. Structural variation in the human genome. Nat. Rev. Genet. 2006;7:85&#x2013;97. doi: 10.1038/nrg1767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg1767</ArticleId><ArticleId IdType="pubmed">16418744</ArticleId></ArticleIdList></Reference><Reference><Citation>Mis M.S.C., Brajkovic S., Tafuri F., Bresolin N., Comi G.P., Corti S. Development of therapeutics for C9orf72 ALS/FTD-related disorders. Mol. Neurobiol. 2017;54:4466&#x2013;4476. doi: 10.1007/s12035-016-9993-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-9993-0</ArticleId><ArticleId IdType="pubmed">27349438</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon P.H. Amyotrophic lateral sclerosis: An update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis. 2013;4:295&#x2013;310. doi: 10.14336/AD.2013.0400295.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2013.0400295</ArticleId><ArticleId IdType="pmc">PMC3794725</ArticleId><ArticleId IdType="pubmed">24124634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandler K., Witzel S., Eder K., Rothenbacher D., Nagel G., Peter R.S., Schuster J., Dorst J., Rosenbohm A., Ludolph A.C. Phenotyping of the thoracic-onset variant of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2022;93:563&#x2013;565. doi: 10.1136/jnnp-2021-326712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-326712</ArticleId><ArticleId IdType="pubmed">34667101</ArticleId></ArticleIdList></Reference><Reference><Citation>Makkonen T., Ruottinen H., Puhto R., Helminen M., Palmio J. Speech deterioration in amyotrophic lateral sclerosis (ALS) after manifestation of bulbar symptoms. Int. J. Lang Commun. Disord. 2018;53:385&#x2013;392. doi: 10.1111/1460-6984.12357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1460-6984.12357</ArticleId><ArticleId IdType="pubmed">29159848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuriakose T., Girish K. Dysarthria and dysphagia in amyotrophic lateral sclerosis: A case study. J. Neurosci. Res. 2020;10:12&#x2013;19.</Citation></Reference><Reference><Citation>Perry B.J., Martino R., Yunusova Y., Plowman E.K., Green J.R. Lingual and jaw kinematic abnormalities precede speech and swallowing impairments in ALS. Dysphagia. 2018;33:840&#x2013;847. doi: 10.1007/s00455-018-9909-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00455-018-9909-4</ArticleId><ArticleId IdType="pmc">PMC6244810</ArticleId><ArticleId IdType="pubmed">29774424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann W., Langner S., Freigang M., Fischer S., Storch A., G&#xfc;nther R., Hermann A. Affection of respiratory muscles in ALS and SMA. J. Clin. Med. 2022;11:1163. doi: 10.3390/jcm11051163.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11051163</ArticleId><ArticleId IdType="pmc">PMC8910994</ArticleId><ArticleId IdType="pubmed">35268254</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoun S., Birks C., Hogden A., Mathers S. Public policy in MND care: The australian perspective. In: Blank R.H., Kurent J.E., Oliver D., editors. Public Policy in ALS/MND Care: An International Perspective. Springer Singapore; Singapore: 2021. pp. 29&#x2013;49.</Citation></Reference><Reference><Citation>T&#xfc;lek Z., &#xd6;zakg&#xfc;l A., Alankaya N., Dik A., Kaya A., &#xdc;nalan P.C., &#xd6;zaydin A.N., &#x130;driso&#x11f;lu H.A. Care burden and related factors among informal caregivers of patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2022:1&#x2013;8. doi: 10.1080/21678421.2022.2079993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2022.2079993</ArticleId><ArticleId IdType="pubmed">35652417</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury A., Mukherjee A., Sinharoy U., Pandit A., Biswas A. Non-motor features of amyotrophic lateral sclerosis: A clinic-based study. Ann. Indian Acad. Neurol. 2021;24:745&#x2013;753. doi: 10.1016/j.jns.2021.119404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.119404</ArticleId><ArticleId IdType="pmc">PMC8680868</ArticleId><ArticleId IdType="pubmed">35002134</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C., Newton J., Lonergan K., Chiwera T., Booth T., Chandran S., Colville S., Heverin M., Mays I., Pal S., et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018;91:e1370&#x2013;e1380. doi: 10.1212/WNL.0000000000006317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006317</ArticleId><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaleri F. Review of amyotrophic lateral sclerosis, Parkinson&#x2019;s and Alzheimer&#x2019;s diseases helps further define pathology of the novel paradigm for Alzheimer&#x2019;s with heavy metals as primary disease cause. Med. Hypotheses. 2015;85:779&#x2013;790. doi: 10.1016/j.mehy.2015.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2015.10.009</ArticleId><ArticleId IdType="pubmed">26604027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R., Kapogiannis D., D. Huey E., Momeni P. FTD and ALS: A tale of two diseases. Curr. Alzheimer Res. 2011;8:273&#x2013;294. doi: 10.2174/156720511795563700.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720511795563700</ArticleId><ArticleId IdType="pmc">PMC3801195</ArticleId><ArticleId IdType="pubmed">21222600</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman S.A., Hardiman O., Al-Chalabi A., Chi&#xf3; A., Savelieff M.G., Kiernan M.C., Feldman E.L. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21:480&#x2013;493. doi: 10.1016/S1474-4422(21)00465-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00465-8</ArticleId><ArticleId IdType="pubmed">35334233</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards D., Morren J.A., Pioro E.P. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J. Neurol. Sci. 2020;417:117054. doi: 10.1016/j.jns.2020.117054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117054</ArticleId><ArticleId IdType="pubmed">32763509</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnsen B., Pugdahl K., Fuglsang-Frederiksen A., Kollewe K., Paracka L., Dengler R., Camdessanch&#xe9; J., Nix W., Liguori R., Schofield I. Diagnostic criteria for amyotrophic lateral sclerosis: A multicentre study of inter-rater variation and sensitivity. Clin. Neurophys. 2019;130:307&#x2013;314. doi: 10.1016/j.clinph.2018.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2018.11.021</ArticleId><ArticleId IdType="pubmed">30573424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannaford A., Pavey N., van den Bos M., Geevasinga N., Menon P., Shefner J.M., Kiernan M.C., Vucic S. Diagnostic utility of gold coast criteria in amyotrophic lateral sclerosis. Ann. Neurol. 2021;89:979&#x2013;986. doi: 10.1002/ana.26045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26045</ArticleId><ArticleId IdType="pubmed">33565111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M.C., Shefner J.M., Kaji R., Burke D. Amyotrophic lateral sclerosis: A new diagnostic paradigm. J. Neurol. Neurosurg. Psychiatry. 2020;91:903&#x2013;904. doi: 10.1136/jnnp-2020-324006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-324006</ArticleId><ArticleId IdType="pubmed">32576616</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen D., Yang X., Wang Y., He D., Sun X., Cai Z., Li J., Liu M., Cui L. The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population. Transl. Neurodegener. 2021;10:28. doi: 10.1186/s40035-021-00253-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00253-2</ArticleId><ArticleId IdType="pmc">PMC8351337</ArticleId><ArticleId IdType="pubmed">34372918</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Nakanishi A. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J. Neurol. Sci. 1999;169:13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M., Jones A., Talbot K., Al-Chalabi A., Turner M.R. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph. Lateral Scler. Front. Degener. 2016;17:414&#x2013;425. doi: 10.3109/21678421.2016.1140786.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1140786</ArticleId><ArticleId IdType="pmc">PMC4950444</ArticleId><ArticleId IdType="pubmed">26864085</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C., Stavrou M., Elliott E., Gregory J.M., Leigh N., Pinto A.A., Williams T.L., Chataway J., Swingler R., Parmar M.K.B., et al. Clinical trials in amyotrophic lateral sclerosis: A systematic review and perspective. Brain Commun. 2021;3:fcab242. doi: 10.1093/braincomms/fcab242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab242</ArticleId><ArticleId IdType="pmc">PMC8659356</ArticleId><ArticleId IdType="pubmed">34901853</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Benatar M. Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve. 2015;51:14&#x2013;18. doi: 10.1002/mus.24470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24470</ArticleId><ArticleId IdType="pmc">PMC4270289</ArticleId><ArticleId IdType="pubmed">25288265</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor B., Zhang H., Shefner J., Schoenfeld D., Cudkowicz M. Functional outcome measures as clinical trial endpoints in ALS. Neurology. 2004;63:1933&#x2013;1935. doi: 10.1212/01.WNL.0000144345.49510.4E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000144345.49510.4E</ArticleId><ArticleId IdType="pubmed">15557515</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzino G., Irrera N., Cucinotta M., Pallio G., Mannino F., Arcoraci V., Squadrito F., Altavilla D., Bitto A. Oxidative stress: Harms and benefits for human health. Oxid. Med. Cell. Longev. 2017;2017:8416763. doi: 10.1155/2017/8416763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/8416763</ArticleId><ArticleId IdType="pmc">PMC5551541</ArticleId><ArticleId IdType="pubmed">28819546</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.Q., Kosten T.R., Zhang X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2013;46:200&#x2013;206. doi: 10.1016/j.pnpbp.2013.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2013.02.015</ArticleId><ArticleId IdType="pubmed">23470289</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorov D.B., Juhaszova M., Sollott S.J. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol. Rev. 2014;94:909&#x2013;950. doi: 10.1152/physrev.00026.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00026.2013</ArticleId><ArticleId IdType="pmc">PMC4101632</ArticleId><ArticleId IdType="pubmed">24987008</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur I., Behl T., Sehgal A., Singh S., Sharma N., Aleya L., Bungau S. Connecting the dots between mitochondrial dysfunction and Parkinson&#x2019;s disorder: Focus mitochondria-targeting therapeutic paradigm in mitigating the disease severity. Environ. Sci. Pollut. Res. 2021;28:37060&#x2013;37081. doi: 10.1007/s11356-021-14619-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11356-021-14619-6</ArticleId><ArticleId IdType="pubmed">34053042</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu H., Chen X., Fu X., Zhang J., Li G., Wang Y., Song J., Ma X., Hu C., Xu X. SOD1G93A Induces a Unique PSAP-Dependent Mitochondrial Apoptosis Pathway via Bax&#x2013;Bak Interaction. Biocell. 2021;45:963. doi: 10.32604/biocell.2021.015297.</Citation><ArticleIdList><ArticleId IdType="doi">10.32604/biocell.2021.015297</ArticleId></ArticleIdList></Reference><Reference><Citation>Abati E., Bresolin N., Comi G., Corti S. Silence superoxide dismutase 1 (SOD1): A promising therapeutic target for amyotrophic lateral sclerosis (ALS) Expert Opin. Ther. Targets. 2020;24:295&#x2013;310. doi: 10.1080/14728222.2020.1738390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2020.1738390</ArticleId><ArticleId IdType="pubmed">32125907</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg K., Graffmo K., Pakkenberg B., Weber M., Nielsen M., Marklund S., Br&#xe4;nnstr&#xf6;m T., Andersen P.M. Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD-associated genes. J. Neurol. Neurosurg. Psychiatry. 2019;90:861&#x2013;869. doi: 10.1136/jnnp-2018-319386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319386</ArticleId><ArticleId IdType="pmc">PMC6691870</ArticleId><ArticleId IdType="pubmed">30992335</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist B.G., Genoud S., Roudeau S., Rookyard A., Abdeen A., Cottam V., Hare D.J., White M., Altvater J., Fifita J.A. Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. Brain. 2022:awac165. doi: 10.1093/brain/awac165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac165</ArticleId><ArticleId IdType="pubmed">35512359</ArticleId></ArticleIdList></Reference><Reference><Citation>Ince P.G., Tomkins J., Slade J.Y., Thatcher N.M., Shaw P.J. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: Molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J. Neuropathol. Exp. Neurol. 1998;57:895&#x2013;904. doi: 10.1097/00005072-199810000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199810000-00002</ArticleId><ArticleId IdType="pubmed">9786240</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangoumau A., Verschueren A., Hammouche E., Papon M.-A., Blasco H., Cherpi-Antar C., Pouget J., Corcia P., Andres C.R., Vourc&#x2019;h P. A novel SOD1 mutation p. V31A identified with a slowly progressive form of amyotrophic lateral sclerosis. Neurobiol. Aging. 2014;35:266.e1&#x2013;266.e4. doi: 10.1016/j.neurobiolaging.2013.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.07.012</ArticleId><ArticleId IdType="pubmed">23954173</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Bassot A., Giuliani F., Simmen T. Amyotrophic lateral sclerosis (ALS): Stressed by dysfunctional mitochondria-endoplasmic reticulum contacts (MERCs) Cells. 2021;10:1789. doi: 10.3390/cells10071789.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10071789</ArticleId><ArticleId IdType="pmc">PMC8304209</ArticleId><ArticleId IdType="pubmed">34359958</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y., Kong Q., Shan X., Tian G., Ilieva H., Cleveland D.W., Rothstein J.D., Borchelt D.R., Wong P.C., Lin C.-L.G. Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS. PLoS ONE. 2008;3:e2849. doi: 10.1371/journal.pone.0002849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0002849</ArticleId><ArticleId IdType="pmc">PMC2481395</ArticleId><ArticleId IdType="pubmed">18682740</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana A.C. Current approaches to enhance glutamate transporter function and expression. J. Neurochem. 2015;134:982&#x2013;1007. doi: 10.1111/jnc.13200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13200</ArticleId><ArticleId IdType="pubmed">26096891</ArticleId></ArticleIdList></Reference><Reference><Citation>Green J.L., Dos Santos W.F., Fontana A.C.K. Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: Opportunities for novel therapeutics development. Biochem. Pharm. 2021;193:114786. doi: 10.1016/j.bcp.2021.114786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2021.114786</ArticleId><ArticleId IdType="pmc">PMC8605998</ArticleId><ArticleId IdType="pubmed">34571003</ArticleId></ArticleIdList></Reference><Reference><Citation>Magi S., Piccirillo S., Amoroso S., Lariccia V. Excitatory amino acid transporters (EAATs): Glutamate transport and beyond. Int. J. Mol. Sci. 2019;20:5674. doi: 10.3390/ijms20225674.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20225674</ArticleId><ArticleId IdType="pmc">PMC6888595</ArticleId><ArticleId IdType="pubmed">31766111</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaram R.S., Gowtham L., Nayak B.S. The role of excitatory neurotransmitter glutamate in brain physiology and pathology. Asian J. Pharm. Clin. Res. 2012;5:1&#x2013;7.</Citation></Reference><Reference><Citation>Vucic S., Rothstein J.D., Kiernan M.C. Advances in treating amyotrophic lateral sclerosis: Insights from pathophysiological studies. Trends Neurosci. 2014;37:433&#x2013;442. doi: 10.1016/j.tins.2014.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.05.006</ArticleId><ArticleId IdType="pubmed">24927875</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews J.A., Jackson C.E., Heiman-Patterson T.D., Bettica P., Brooks B.R., Pioro E.P. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2020;21:509&#x2013;518. doi: 10.1080/21678421.2020.1771734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh J.N., Rossor A.M., Fellows A.D., Tosolini A.P., Schiavo G. Axonal transport and neurological disease. Nat. Rev. Neurol. 2019;15:691&#x2013;703. doi: 10.1038/s41582-019-0257-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0257-2</ArticleId><ArticleId IdType="pubmed">31558780</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S., Julien J. Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci. 2013;14:161&#x2013;176. doi: 10.1038/nrn3380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3380</ArticleId><ArticleId IdType="pubmed">23361386</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos K.J., Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research? Neurobiol. Dis. 2017;105:283&#x2013;299. doi: 10.1016/j.nbd.2017.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2017.02.004</ArticleId><ArticleId IdType="pmc">PMC5536153</ArticleId><ArticleId IdType="pubmed">28235672</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F., West P.K., Brennan S., Petrovi&#x107; B., Hooshmand K., Akkari P.A., Keon M., Guennewig B. New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis. Transl. Neurodegener. 2021;10:46. doi: 10.1186/s40035-021-00272-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00272-z</ArticleId><ArticleId IdType="pmc">PMC8597313</ArticleId><ArticleId IdType="pubmed">34789332</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilsland L.G., Sahai E., Kelly G., Golding M., Greensmith L., Schiavo G. Deficits in axonal transport precede ALS symptoms in vivo. Proc. Natl. Acad. Sci. USA. 2010;107:20523&#x2013;20528. doi: 10.1073/pnas.1006869107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1006869107</ArticleId><ArticleId IdType="pmc">PMC2996651</ArticleId><ArticleId IdType="pubmed">21059924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka K., Katsuno M., Kawai K., Ishigaki S., Tanaka F., Sobue G. Disruption of axonal transport in motor neuron diseases. Int. J. Mol. Sci. 2012;13:1225&#x2013;1238. doi: 10.3390/ijms13011225.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms13011225</ArticleId><ArticleId IdType="pmc">PMC3269748</ArticleId><ArticleId IdType="pubmed">22312314</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gregorio S.E. Protein misfolding toxicity and inclusion formation in cellular models of neurodegeneration. Transl. Neruodegener. 2021;6:7775. doi: 10.1186/s40035-017-0077-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-017-0077-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Ji Y., Wang W., Zhang L., Chen Z., Yu M., Shen Y., Ding F., Gu X., Sun H. Amyotrophic Lateral Sclerosis: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies. Antioxidants. 2021;10:1012. doi: 10.3390/antiox10071012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10071012</ArticleId><ArticleId IdType="pmc">PMC8300638</ArticleId><ArticleId IdType="pubmed">34202494</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox L.M., Yamamoto A. Macroautophagy of aggregation-prone proteins in neurodegenerative disease. In: Hayat M.A., editor. Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging. Volume 7. Academic Press; Cambridge, MA, USA: 2015. pp. 117&#x2013;137.</Citation></Reference><Reference><Citation>Gosset P., Camu W., Raoul C., Mezghrani A. Prionoids in amyotrophic lateral sclerosis. Brain Commun. 2022;4:fcac145. doi: 10.1093/braincomms/fcac145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac145</ArticleId><ArticleId IdType="pmc">PMC9242622</ArticleId><ArticleId IdType="pubmed">35783556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal-Conde L.D., Ramos-Acevedo R., Reyes-Hern&#xe1;ndez M.A., Balbuena-Olvera A.J., Morales-Moreno I.D., Arg&#xfc;ero-S&#xe1;nchez R., Sch&#xfc;le B., Guerra-Crespo M. Alpha-synuclein physiology and pathology: A perspective on cellular structures and organelles. Front. Neurosci. 2020;13:1399. doi: 10.3389/fnins.2019.01399.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01399</ArticleId><ArticleId IdType="pmc">PMC6989544</ArticleId><ArticleId IdType="pubmed">32038126</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa T., Sugeno N., Kikuchi A., Baba T., Aoki M. Membrane trafficking illuminates a path to Parkinson&#x2019;s disease. Tohoku J. Exp. Med. 2017;242:63&#x2013;76. doi: 10.1620/tjem.242.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1620/tjem.242.63</ArticleId><ArticleId IdType="pubmed">28539529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugeno N., J&#xe4;ckel S., Voigt A., Wassouf Z., Schulze-Hentrich J., Kahle P.J. &#x3b1;-Synuclein enhances histone H3 lysine-9 dimethylation and H3K9me2-dependent transcriptional responses. Sci. Rep. 2016;6:36328. doi: 10.1038/srep36328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36328</ArticleId><ArticleId IdType="pmc">PMC5093762</ArticleId><ArticleId IdType="pubmed">27808254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellani S., Sousa V.L., Ronzitti G., Valtorta F., Meldolesi J., Chieregatti E. The regulation of synaptic function by &#x3b1;-synuclein. Commun. Integr. Biol. 2010;3:106&#x2013;109. doi: 10.4161/cib.3.2.10964.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cib.3.2.10964</ArticleId><ArticleId IdType="pmc">PMC2889964</ArticleId><ArticleId IdType="pubmed">20585500</ArticleId></ArticleIdList></Reference><Reference><Citation>Parihar A., Parihar P., Solanki I., Parihar M.S. Alpha synuclein and Parkinson&#x2019;s disease. In: Singh S., Joshi N., editors. Pathology, Prevention and Therapeutics of Neurodegenerative Disease. 1st ed. Springer; Singapore: 2019. pp. 1&#x2013;14.</Citation></Reference><Reference><Citation>Marti M.J., Tolosa E., Campdelacreu J. Clinical overview of the synucleinopathies. Mov. Disord. 2003;18((Suppl. 6)):S21&#x2013;S27. doi: 10.1002/mds.10559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.10559</ArticleId><ArticleId IdType="pubmed">14502652</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerman A.L., Watts J.C., Aoyagi A., Giles K., Middleton L.T., Prusiner S.B. &#x3b1;-Synuclein: Multiple System Atrophy Prions. Cold Spring Harb. Perspect. Med. 2018;12:a024588. doi: 10.1101/cshperspect.a024588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024588</ArticleId><ArticleId IdType="pmc">PMC5561534</ArticleId><ArticleId IdType="pubmed">28213437</ArticleId></ArticleIdList></Reference><Reference><Citation>Visanji N.P., Lang A.E., Kovacs G.G. Beyond the synucleinopathies: Apha-synuclein as a driving force in neurodegenerative comorbidities. Transl. Neurodegener. 2019;8:28. doi: 10.1186/s40035-019-0172-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-019-0172-x</ArticleId><ArticleId IdType="pmc">PMC6727368</ArticleId><ArticleId IdType="pubmed">31508228</ArticleId></ArticleIdList></Reference><Reference><Citation>Barba L., Paolini Paoletti F., Bellomo G., Gaetani L., Halbgebauer S., Oeckl P., Otto M., Parnetti L. Alpha and beta synucleins: From pathophysiology to clinical application as biomarkers. Mov. Disord. 2022;37:669&#x2013;683. doi: 10.1002/mds.28941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28941</ArticleId><ArticleId IdType="pmc">PMC9303453</ArticleId><ArticleId IdType="pubmed">35122299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson&#x2019;s disease. Nat. Med. 2008;14:504&#x2013;506. doi: 10.1038/nm1747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1747</ArticleId><ArticleId IdType="pubmed">18391962</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad S., Katta M.R., Abhishek S., Sridhar R., Valisekka S.S., Hameed M., Kaur J., Walia N. Recent advances in Lewy body dementia: A comprehensive review. Dis. Mon. 2022 doi: 10.1016/j.disamonth.2022.101441. in press .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.disamonth.2022.101441</ArticleId><ArticleId IdType="pubmed">35690493</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., Trojanowski J.Q., Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson&#x2019;s disease and dementia with Lewy bodies. Am. J. Pathol. 1998;152:879&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858234</ArticleId><ArticleId IdType="pubmed">9546347</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro T.F., Koss D.J., Erskine D., Walker L., Kurzawa-Akanbi M., Burn D., Donaghy P., Morris C., Taylor J.P., Thomas A., et al. Dementia with Lewy bodies: An update and outlook. Mol. Neurodegener. 2019;14:5. doi: 10.1186/s13024-019-0306-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0306-8</ArticleId><ArticleId IdType="pmc">PMC6341685</ArticleId><ArticleId IdType="pubmed">30665447</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng J., Olrichs N.K., Gadella B.M., Kaloyanova D.V., Helms J.B. Regulation of functional protein aggregation by multiple factors: Implications for the amyloidogenic behavior of the cap superfamily proteins. Int. J. Mol. Sci. 2020;21:6530. doi: 10.3390/ijms21186530.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21186530</ArticleId><ArticleId IdType="pmc">PMC7554809</ArticleId><ArticleId IdType="pubmed">32906672</ArticleId></ArticleIdList></Reference><Reference><Citation>Puspita L., Chung S.Y., Shim J.-W. Oxidative stress and cellular pathologies in Parkinson&#x2019;s disease. Mol. Brain. 2017;10:53. doi: 10.1186/s13041-017-0340-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0340-9</ArticleId><ArticleId IdType="pmc">PMC5706368</ArticleId><ArticleId IdType="pubmed">29183391</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz-Schaeffer W.J. The synaptic pathology of &#x3b1;-synuclein aggregation in dementia with Lewy bodies, Parkinson&#x2019;s disease and Parkinson&#x2019;s disease dementia. Acta Neuropathol. 2010;120:131&#x2013;143. doi: 10.1007/s00401-010-0711-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0711-0</ArticleId><ArticleId IdType="pmc">PMC2892607</ArticleId><ArticleId IdType="pubmed">20563819</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubellini P., Picconi B., Di Filippo M., Calabresi P. Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: From experimental models to neurodegenerative diseases. Biochim. Biophys. Acta Mol. Basis Dis. 2010;1802:151&#x2013;161. doi: 10.1016/j.bbadis.2009.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2009.08.001</ArticleId><ArticleId IdType="pubmed">19683569</ArticleId></ArticleIdList></Reference><Reference><Citation>Helferich A.M., Ruf W.P., Grozdanov V., Freischmidt A., Feiler M.S., Zondler L., Ludolph A.C., McLean P.J., Weishaupt J.H., Danzer K.M. &#x3b1;-synuclein interacts with SOD1 and promotes its oligomerization. Mol. Neurodegener. 2015;10:66. doi: 10.1186/s13024-015-0062-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-015-0062-3</ArticleId><ArticleId IdType="pmc">PMC4672499</ArticleId><ArticleId IdType="pubmed">26643113</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist B.G., Davies K.M., Cottam V., Genoud S., Ortega R., Roudeau S., Carmona A., De Silva K., Wasinger V., Lewis S.J. Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson&#x2019;s disease brain. Acta Neuropathol. 2017;134:113&#x2013;127. doi: 10.1007/s00401-017-1726-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1726-6</ArticleId><ArticleId IdType="pubmed">28527045</ArticleId></ArticleIdList></Reference><Reference><Citation>Trist B.G., Fifita J.A., Freckleton S.E., Hare D.J., Lewis S.J.G., Halliday G.M., Blair I.P., Double K.L. Accumulation of dysfunctional SOD1 protein in Parkinson&#x2019;s disease is not associated with mutations in the SOD1 gene. Acta Neuropathol. 2018;135:155&#x2013;156. doi: 10.1007/s00401-017-1779-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1779-6</ArticleId><ArticleId IdType="pubmed">29052003</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde T.E., Miller V.M. Proteinopathy-induced neuronal senescence: A hypothesis for brain failure in Alzheimer&#x2019;s and other neurodegenerative diseases. Alzheimers Res. Ther. 2009;1:5. doi: 10.1186/alzrt5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt5</ArticleId><ArticleId IdType="pmc">PMC2874257</ArticleId><ArticleId IdType="pubmed">19822029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi A., Takeda A., Okamura N., Tashiro M., Hasegawa T., Furumoto S., Kobayashi M., Sugeno N., Baba T., Miki Y. In vivo visualization of &#x3b1;-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl) ethenyl]-6-[2-(fluoro) ethoxy] benzoxazole positron emission tomography in multiple system atrophy. Brain. 2010;133:1772&#x2013;1778. doi: 10.1093/brain/awq091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq091</ArticleId><ArticleId IdType="pubmed">20430832</ArticleId></ArticleIdList></Reference><Reference><Citation>Han W., Liu Y., Mi Y., Zhao J., Liu D., Tian Q. Alpha-synuclein (SNCA) polymorphisms and susceptibility to Parkinson&#x2019;s disease: A meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2015;168B:123&#x2013;134. doi: 10.1002/ajmg.b.32288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.32288</ArticleId><ArticleId IdType="pubmed">25656566</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahul-Mellier A.-L., Burtscher J., Maharjan N., Weerens L., Croisier M., Kuttler F., Leleu M., Knott G.W., Lashuel H.A. The process of Lewy body formation, rather than simply &#x3b1;-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl. Acad. Sci. USA. 2020;117:4971&#x2013;4982. doi: 10.1073/pnas.1913904117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1913904117</ArticleId><ArticleId IdType="pmc">PMC7060668</ArticleId><ArticleId IdType="pubmed">32075919</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferese R., Modugno N., Campopiano R., Santilli M., Zampatti S., Giardina E., Nardone A., Postorivo D., Fornai F., Novelli G. Four copies of SNCA responsible for autosomal dominant Parkinson&#x2019;s disease in two Italian siblings. Parkinson&#x2019;s Dis. 2015;2015:546462. doi: 10.1155/2015/546462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/546462</ArticleId><ArticleId IdType="pmc">PMC4655296</ArticleId><ArticleId IdType="pubmed">26635992</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasanen P., Myllykangas L., Siitonen M., Raunio A., Kaakkola S., Lyytinen J., Tienari P.J., P&#xf6;yh&#xf6;nen M., Paetau A. A novel &#x3b1;-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson&#x2019;s disease-type pathology. Neurobiol. Aging. 2014;35:2180.e1&#x2013;2180.e5. doi: 10.1016/j.neurobiolaging.2014.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.03.024</ArticleId><ArticleId IdType="pubmed">24746362</ArticleId></ArticleIdList></Reference><Reference><Citation>Magistrelli L., Contaldi E., Comi C. The impact of SNCA variations and its product alpha-synuclein on non-motor features of parkinson&#x2019;s disease. Life. 2021;11:804. doi: 10.3390/life11080804.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11080804</ArticleId><ArticleId IdType="pmc">PMC8401994</ArticleId><ArticleId IdType="pubmed">34440548</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R. Mutation in the &#x3b1;-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276:2045&#x2013;2047. doi: 10.1126/science.276.5321.2045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.276.5321.2045</ArticleId><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840. doi: 10.1038/42166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/42166</ArticleId><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabin D.E., Gispert-Sanchez S., Murphy D., Auburger G., Myers R.R., Nussbaum R.L. Exacerbated synucleinopathy in mice expressing A53T SNCA on a SNCA null background. Neurobiol. Aging. 2005;26:25&#x2013;35. doi: 10.1016/j.neurobiolaging.2004.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.02.026</ArticleId><ArticleId IdType="pubmed">15585343</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., Lee M.K. Parkinson&#x2019;s disease &#x3b1;-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 2006;26:41&#x2013;50. doi: 10.1523/JNEUROSCI.4308-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4308-05.2006</ArticleId><ArticleId IdType="pmc">PMC6381830</ArticleId><ArticleId IdType="pubmed">16399671</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y., de Silva H.R., Rosi B.L., Yamaoka L.H., Rimmler J.B., Pericak-Vance M.A., Roses A.D., Chen X., Masliah E., Deteresa R. Genetic studies in Alzheimer&#x2019;s disease with an NACP/&#x3b1;-synuclein polymorphism. Ann. Neurol. 1996;40:207&#x2013;215. doi: 10.1002/ana.410400212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410400212</ArticleId><ArticleId IdType="pubmed">8773602</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado L., De Marchi F., Tunesi S., Oggioni G.D., Carecchio M., Magistrelli L., Tesei S., Riboldazzi G., Di Fonzo A., Locci C. The length of SNCA Rep1 microsatellite may influence cognitive evolution in Parkinson&#x2019;s disease. Front. Neurol. 2018;9:213. doi: 10.3389/fneur.2018.00213.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00213</ArticleId><ArticleId IdType="pmc">PMC5890103</ArticleId><ArticleId IdType="pubmed">29662465</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman S.M., Umbach D.M., Kamel F., Tanner C.M. Head injury, &#x3b1;-synuclein Rep1 and Parkinson&#x2019;s disease: A meta-analytic view of gene-environment interaction. Eur. J. Neurol. 2015;22:e75. doi: 10.1111/ene.12694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12694</ArticleId><ArticleId IdType="pubmed">26060929</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnertz C., Lutz M.W., Ervin J.F., Allen J., Miller N.R., Welsh-Bohmer K.A., Roses A.D., Chiba-Falek O. The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer&#x2019;s disease. Hum. Mol. Genet. 2014;23:4814&#x2013;4821. doi: 10.1093/hmg/ddu196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu196</ArticleId><ArticleId IdType="pmc">PMC4140463</ArticleId><ArticleId IdType="pubmed">24777780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng A.S., Tan Y.J., Zhao Y., Saffari S.E., Lu Z., Ng E.Y., Ng S.Y., Chia N.S., Setiawan F., Xu Z. SNCA Rep1 promoter variability influences cognition in Parkinson&#x2019;s disease. Mov. Disord. 2019;34:1232&#x2013;1236. doi: 10.1002/mds.27768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27768</ArticleId><ArticleId IdType="pubmed">31234238</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldner F., Stelzer Y., Shivalila C.S., Abraham B.J., Latourelle J.C., Barrasa M.I., Goldmann J., Myers R.H., Young R.A., Jaenisch R. Parkinson-associated risk variant in distal enhancer of &#x3b1;-synuclein modulates target gene expression. Nature. 2016;533:95&#x2013;99. doi: 10.1038/nature17939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17939</ArticleId><ArticleId IdType="pmc">PMC5042324</ArticleId><ArticleId IdType="pubmed">27096366</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiba-Falek O. Structural variants in SNCA gene and the implication to synucleinopathies. Curr. Opin. Genet. Dev. 2017;44:110&#x2013;116. doi: 10.1016/j.gde.2017.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2017.01.014</ArticleId><ArticleId IdType="pmc">PMC5447477</ArticleId><ArticleId IdType="pubmed">28319736</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamzadeh F.N., Surguchov A. Parkinson&#x2019;s disease: Biomarkers, treatment, and risk factors. Front. Neurol. 2018;12:612. doi: 10.3389/fnins.2018.00612.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00612</ArticleId><ArticleId IdType="pmc">PMC6125353</ArticleId><ArticleId IdType="pubmed">30214392</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai B., Marion S., Teschke K., Tsui J. Occupational and environmental risk factors for Parkinson&#x2019;s disease. Parkinsonism Relat. Disord. 2002;8:297&#x2013;309. doi: 10.1016/S1353-8020(01)00054-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1353-8020(01)00054-2</ArticleId><ArticleId IdType="pubmed">15177059</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingelhoefer L., Reichmann H. Pathogenesis of Parkinson disease&#x2014;The gut-brain axis and environmental factors. Nat. Rev. Neurol. 2015;11:625&#x2013;636. doi: 10.1038/nrneurol.2015.197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2015.197</ArticleId><ArticleId IdType="pubmed">26503923</ArticleId></ArticleIdList></Reference><Reference><Citation>Innos J., Hickey M.A. Using rotenone to model Parkinson&#x2019;s disease in mice: A review of the role of pharmacokinetics. Chem. Res. Toxicol. 2021;34:1223&#x2013;1239. doi: 10.1021/acs.chemrestox.0c00522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrestox.0c00522</ArticleId><ArticleId IdType="pubmed">33961406</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustapha M., Taib C.N.M. MPTP-induced mouse model of Parkinson&#x2019;s disease: A promising direction for therapeutic strategies. Bosn. J. Basic Med. Sci. 2021;21:422. doi: 10.17305/bjbms.2020.5181.</Citation><ArticleIdList><ArticleId IdType="doi">10.17305/bjbms.2020.5181</ArticleId><ArticleId IdType="pmc">PMC8292858</ArticleId><ArticleId IdType="pubmed">33357211</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport. 2000;11:211&#x2013;213. doi: 10.1097/00001756-200001170-00041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200001170-00041</ArticleId><ArticleId IdType="pubmed">10683860</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues L.S., Targa A.D., Noseda A.C.D., Aurich M.F., Da Cunha C., Lima M.M. Olfactory impairment in the rotenone model of Parkinson&#x2019;s disease is associated with bulbar dopaminergic D2 activity after REM sleep deprivation. Front. Cell Neurosci. 2014;8:383. doi: 10.3389/fncel.2014.00383.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00383</ArticleId><ArticleId IdType="pmc">PMC4249459</ArticleId><ArticleId IdType="pubmed">25520618</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagac A. Farming, well water consumption, rural living, and pesticide exposure in early life as the risk factors for Parkinson disease in I&#x11f;d&#x131;r province. Neurosci. J. 2020;25:129&#x2013;135. doi: 10.17712/nsj.2020.2.20190104.</Citation><ArticleIdList><ArticleId IdType="doi">10.17712/nsj.2020.2.20190104</ArticleId><ArticleId IdType="pmc">PMC8015530</ArticleId><ArticleId IdType="pubmed">32351250</ArticleId></ArticleIdList></Reference><Reference><Citation>Kori R.K., Singh M.K., Jain A.K., Yadav R.S. Neurochemical and behavioral dysfunctions in pesticide exposed farm workers: A clinical outcome. Indian J. Clin. Biochem. 2018;33:372&#x2013;381. doi: 10.1007/s12291-018-0791-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12291-018-0791-5</ArticleId><ArticleId IdType="pmc">PMC6170243</ArticleId><ArticleId IdType="pubmed">30319182</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Wang Z. Advances in Parkinson&#x2019;s disease induced by &#x3b1;-synuclein transmitted through the gut-brain axis. Shengwu Gongcheng Xuebao/Chin. J. Biotechnol. 2022;38:2120&#x2013;2127. doi: 10.13345/j.cjb.210822.</Citation><ArticleIdList><ArticleId IdType="doi">10.13345/j.cjb.210822</ArticleId><ArticleId IdType="pubmed">35786466</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteves A.R., Munoz-Pinto M.F., Nunes-Costa D., Candeias E., Silva D.F., Magalh&#xe3;es J.D., Pereira-Santos A.R., Ferreira I.L., Alarico S., Tiago I. Footprints of a microbial toxin from the gut microbiome to mesencephalic mitochondria. Gut. 2021:1&#x2013;17. doi: 10.1136/gutjnl-2021-326023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-326023</ArticleId><ArticleId IdType="pubmed">34836918</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes-Costa D., Magalh&#xe3;es J.D., G-Fernandes M., Cardoso S.M., Empadinhas N. Microbial BMAA and the pathway for Parkinson&#x2019;s disease neurodegeneration. Front. Aging Neurosci. 2020;12:26. doi: 10.3389/fnagi.2020.00026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00026</ArticleId><ArticleId IdType="pmc">PMC7019015</ArticleId><ArticleId IdType="pubmed">32317956</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierozan P., Piras E., Brittebo E., Karlsson O. The cyanobacterial neurotoxin &#x3b2;-N-methylamino-l-alanine (BMAA) targets the olfactory bulb region. Arch Toxicol. 2020;94:2799&#x2013;2808. doi: 10.1007/s00204-020-02775-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00204-020-02775-6</ArticleId><ArticleId IdType="pmc">PMC7395073</ArticleId><ArticleId IdType="pubmed">32435914</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzuhara S. Revisit to Kii ALS&#x2014;The innovated concept of ALS-Parkinsonism-dementia complex, clinicopathological features, epidemiology and etiology. Brain Nerve. 2007;59:1065&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">17969346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokubo Y., Taniguchi A., Hasegawa M., Hayakawa Y., Morimoto S., Yoneda M., Hirokawa Y., Shiraishi T., Saito Y., Murayama S. &#x3b1;-Synuclein pathology in the amyotrophic lateral sclerosis/parkinsonism dementia complex in the Kii Peninsula, Japan. J. Neuropathol. Exp. Neurol. 2012;71:625&#x2013;630. doi: 10.1097/NEN.0b013e31825b9680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825b9680</ArticleId><ArticleId IdType="pubmed">22710962</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan M.W., Steele J.C., Kopin I.J., Markey S.P. 2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flour: An unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology. 1990;40:767. doi: 10.1212/WNL.40.5.767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.40.5.767</ArticleId><ArticleId IdType="pubmed">2330104</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan M., Kopin I., Garruto R., Lavine L., Markey S. 2-Amino-3 (methylamino)-propionic acid in cycad-derived foods is an unlikely cause of amyotrophic lateral sclerosis/parkinsonism. Lancet. 1988;332:631&#x2013;632. doi: 10.1016/S0140-6736(88)90671-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(88)90671-X</ArticleId><ArticleId IdType="pubmed">2901010</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley W.G., Mash D.C. Beyond Guam: The cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. Amyotroph. Lateral Scler. 2009;10:7&#x2013;20. doi: 10.3109/17482960903286009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903286009</ArticleId><ArticleId IdType="pubmed">19929726</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor E.A., Mowrey D.D., Dokholyan N.V. &#x3b2;-Methylamino-L-alanine substitution of serine in SOD1 suggests a direct role in ALS etiology. PLoS Comp. Biol. 2019;15:e1007225. doi: 10.1371/journal.pcbi.1007225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1007225</ArticleId><ArticleId IdType="pmc">PMC6668853</ArticleId><ArticleId IdType="pubmed">31323035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanem S.S., Majbour N.K., Vaikath N.N., Ardah M.T., Erskine D., Jensen N.M., Fayyad M., Sudhakaran I.P., Vasili E., Melachroinou K. &#x3b1;-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc. Natl. Acad. Sci. USA. 2022;119:e2109617119. doi: 10.1073/pnas.2109617119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2109617119</ArticleId><ArticleId IdType="pmc">PMC9169642</ArticleId><ArticleId IdType="pubmed">35353605</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A., Chio A., Pagani M., Cammarosano S., Dematteis F., Moglia C., Solero L., Manera U., Martone T., Brunetti M., et al. Parkinsonian traits in amyotrophic lateral sclerosis (ALS): A prospective population-based study. J. Neurol. 2019;266:1633&#x2013;1642. doi: 10.1007/s00415-019-09305-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09305-0</ArticleId><ArticleId IdType="pubmed">30949819</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda K., Katayama S., Watanabe C., Yamamura Y., Nakamura S., Yonehara S., Inai K. Pure autonomic failure with motor neuron disease: Report of a clinical study and postmortem examination of a patient. J. Neurol. Neurosurg. Psychiatry. 1996;60:351&#x2013;352. doi: 10.1136/jnnp.60.3.351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.60.3.351</ArticleId><ArticleId IdType="pmc">PMC1073871</ArticleId><ArticleId IdType="pubmed">8609525</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty M.J., Bird T.D., Leverenz J.B. &#x3b1;-synuclein in motor neuron disease: An immunohistologic study. Acta Neuropathol. 2004;107:169&#x2013;175. doi: 10.1007/s00401-003-0790-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-003-0790-2</ArticleId><ArticleId IdType="pubmed">14648076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezey E., Dehejia A., Harta G., Papp M.I., Polymeropoulos M.H., Brownstein M.J. Alpha synuclein in neurodegenerative disorders: Murderer or accomplice? Nat. Med. 1998;4:755&#x2013;757. doi: 10.1038/nm0798-755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0798-755</ArticleId><ArticleId IdType="pubmed">9662355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y.H., Joo K.M., Kim M.J., Cha C.I. Immunohistochemical study on the distribution of alpha-synuclein in the central nervous system of transgenic mice expressing a human Cu/Zn superoxide dismutase mutation. Neurosci. Lett. 2003;342:151&#x2013;154. doi: 10.1016/S0304-3940(03)00237-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(03)00237-4</ArticleId><ArticleId IdType="pubmed">12757887</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei Y., Oguchi K., Koshihara H., Hineno A., Nakamura A., Ohara S. &#x3b1;-Synuclein coaggregation in familial amyotrophic lateral sclerosis with SOD1 gene mutation. Hum. Pathol. 2013;44:1171&#x2013;1176. doi: 10.1016/j.humpath.2012.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humpath.2012.10.024</ArticleId><ArticleId IdType="pubmed">23352207</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang E.J., Choi S.-M. &#x3b1;-Synuclein modification in an ALS animal model. Evid. Based Complement. Altern. 2013;2013:259381. doi: 10.1155/2013/259381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/259381</ArticleId><ArticleId IdType="pmc">PMC3666397</ArticleId><ArticleId IdType="pubmed">23762114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.H., Jung S.Y., Lee K.-W., Lee S.H., Cai M., Choi S.-M., Yang E.J. Bee venom effects on ubiquitin proteasome system in hSOD1G85R-expressing NSC34 motor neuron cells. BMC Comp. Altern. Med. 2013;13:179. doi: 10.1186/1472-6882-13-179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6882-13-179</ArticleId><ArticleId IdType="pmc">PMC3722004</ArticleId><ArticleId IdType="pubmed">23866691</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch Y., Helferich A.M., Steinacker P., Oeckl P., Walther P., Weishaupt J.H., Danzer K.M., Otto M. Aggregated &#x3b1;-Synuclein increases SOD1 oligomerization in a mouse model of amyotrophic lateral sclerosis. Am. J. Clin. Pathol. 2016;186:2152&#x2013;2161. doi: 10.1016/j.ajpath.2016.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2016.04.008</ArticleId><ArticleId IdType="pubmed">27322773</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X.Y., Chen Y.P., Song W., Zhao B., Cao B., Wei Q.Q., Ou R.W., Yang Y., Yuan L.X., Shang H.-F. SNCA variants rs2736990 and rs356220 as risk factors for Parkinson&#x2019;s disease but not for amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population. Neurobiol. Aging. 2014;35:e2881&#x2013;e2882. doi: 10.1016/j.neurobiolaging.2014.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.07.014</ArticleId><ArticleId IdType="pubmed">25129240</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wei Q.Q., Ou R., Cao B., Chen X., Zhao B., Guo X., Yang Y., Chen K., Wu Y., et al. Genetic variants of SNCA are associated with susceptibility to Parkinson&#x2019;s disease but not amyotrophic lateral sclerosis or multiple system atrophy in a Chinese population. PLoS ONE. 2015;10:e0133776. doi: 10.1371/journal.pone.0133776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133776</ArticleId><ArticleId IdType="pmc">PMC4514852</ArticleId><ArticleId IdType="pubmed">26208350</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchiano V., Bartoletti-Stella A., Rizzo G., Avoni P., Parchi P., Salvi F., Liguori R., Capellari S. Frequency of Parkinson&#x2019;s disease genes and role of PARK2 in amyotrophic lateral sclerosis: An NGS study. Genes. 2022;13:1306. doi: 10.3390/genes13081306.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13081306</ArticleId><ArticleId IdType="pmc">PMC9332209</ArticleId><ArticleId IdType="pubmed">35893043</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen W., Shatunov A., Dekker A.M., McLaughlin R.L., Diekstra F.P., Pulit S.L., van der Spek R.A.A., V&#xf5;sa U., de Jong S., Robinson M.R., et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1043&#x2013;1048. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda S., Sano T., Nishikawa N., Mikasa M., Takahashi Y., Takao M. Amyotrophic lateral sclerosis with muscle weakness and dropped head during the course of Parkinson&#x2019;s disease: An autopsy case. Clin. Neurol. 2021;61:373&#x2013;377. doi: 10.5692/clinicalneurol.cn-001546.</Citation><ArticleIdList><ArticleId IdType="doi">10.5692/clinicalneurol.cn-001546</ArticleId><ArticleId IdType="pubmed">34011808</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T., Itoh K., Matsuo K., Yamamoto Y., Hosokawa Y., Koizumi T., Shiga K., Mizuno T., Nakagawa M., Fushiki S. Concomitant alpha-synuclein pathology in an autopsy case of amyotrophic lateral sclerosis presenting with orthostatic hypotension and cardiac arrests. Neuropath. 2014;34:164&#x2013;169. doi: 10.1111/neup.12057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12057</ArticleId><ArticleId IdType="pubmed">23898972</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian T., Huang C., Tong J., Yang M., Zhou H., Xia X.-G. TDP-43 potentiates alpha-synuclein toxicity to dopaminergic neurons in transgenic mice. Int. J. Biol. Sci. 2011;7:234&#x2013;243. doi: 10.7150/ijbs.7.234.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.7.234</ArticleId><ArticleId IdType="pmc">PMC3053535</ArticleId><ArticleId IdType="pubmed">21448284</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakal S., Wyant C.E., George H.E., Morgan S.E., Rangachari V. Prion-like C-terminal domain of TDP-43 and &#x3b1;-Synuclein interact synergistically to generate neurotoxic hybrid fibrils. J. Mol. Biol. 2021;433:166953. doi: 10.1016/j.jmb.2021.166953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2021.166953</ArticleId><ArticleId IdType="pmc">PMC8085152</ArticleId><ArticleId IdType="pubmed">33771571</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson J.L., Lee E.B., Xie S.X., Rennert L., Suh E., Bredenberg C., Caswell C., Van Deerlin V.M., Yan N., Yousef A. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141:2181&#x2013;2193. doi: 10.1093/brain/awy146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy146</ArticleId><ArticleId IdType="pmc">PMC6022546</ArticleId><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H., Uryu K., Robinson J., Xie S.X., Hurtig H., Duda J.E., Arnold S.E., Siderowf A., Grossman M., Leverenz J.B. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114:221&#x2013;229. doi: 10.1007/s00401-007-0261-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0261-2</ArticleId><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridi J.C., Hirth F. Mechanisms of &#x3b1;-synuclein induced synaptopathy in Parkinson&#x2019;s disease. Front. Neurosci. 2018;12:80. doi: 10.3389/fnins.2018.00080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00080</ArticleId><ArticleId IdType="pmc">PMC5825910</ArticleId><ArticleId IdType="pubmed">29515354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M., Mackie P.M., Shaerzadeh F., Gamble-George J., Miller D.R., Martyniuk C.J., Khoshbouei H. In Parkinson&#x2019;s patient-derived dopamine neurons, the triplication of &#x3b1;-synuclein locus induces distinctive firing pattern by impeding D2 receptor autoinhibition. Acta Neuropathol. Commun. 2021;9:107. doi: 10.1186/s40478-021-01203-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01203-9</ArticleId><ArticleId IdType="pmc">PMC8185945</ArticleId><ArticleId IdType="pubmed">34099060</ArticleId></ArticleIdList></Reference><Reference><Citation>Courte J., Bousset L., Boxberg Y.V., Villard C., Melki R., Peyrin J.-M. The expression level of alpha-synuclein in different neuronal populations is the primary determinant of its prion-like seeding. Sci. Rep. 2020;10:4895. doi: 10.1038/s41598-020-61757-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-61757-x</ArticleId><ArticleId IdType="pmc">PMC7078319</ArticleId><ArticleId IdType="pubmed">32184415</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M.-Y. Neuronal &#x3b1;-synucleinopathy with severe movement disorder in mice expressing A53T human &#x3b1;-synuclein. Neuron. 2002;34:521&#x2013;533. doi: 10.1016/S0896-6273(02)00682-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00682-7</ArticleId><ArticleId IdType="pubmed">12062037</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer B., Barbieri S., Hofele K., Wiederhold K.-H., Probst A., Mistl C., Danner S., Kauffmann S., Spooren W., Tolnay M. Mouse models of &#x3b1;-synucleinopathy and Lewy pathology. Exp. Gerontol. 2000;35:1389&#x2013;1403. doi: 10.1016/S0531-5565(00)00181-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0531-5565(00)00181-9</ArticleId><ArticleId IdType="pubmed">11113617</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Putten H., Wiederhold K.-H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A. Neuropathology in mice expressing human &#x3b1;-synuclein. J. Neurosci. 2000;20:6021&#x2013;6029. doi: 10.1523/JNEUROSCI.20-16-06021.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-16-06021.2000</ArticleId><ArticleId IdType="pmc">PMC6772584</ArticleId><ArticleId IdType="pubmed">10934251</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G.-Y., Liu J., Wang Y.-C., Wang Z.-Y., Hu Y., Xia Q.-J., Xu Y., Shang F.-F., Chen M.-R., Wang F. Effects of alpha-synuclein on primary spinal cord neurons associated with apoptosis and CNTF expression. Cell. Mol. Neruobiol. 2017;37:817&#x2013;829. doi: 10.1007/s10571-016-0420-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-016-0420-x</ArticleId><ArticleId IdType="pubmed">27581683</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumikura H., Takao M., Hatsuta H., Ito S., Nakano Y., Uchino A., Nogami A., Saito Y., Mochizuki H., Murayama S. Distribution of &#x3b1;-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons. Acta Neuropathol. Commun. 2015;3:57. doi: 10.1186/s40478-015-0236-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0236-9</ArticleId><ArticleId IdType="pmc">PMC4571135</ArticleId><ArticleId IdType="pubmed">26374630</ArticleId></ArticleIdList></Reference><Reference><Citation>Caviness J.N., Smith B.E., Stevens J.C., Adler C.H., Caselli R.J., Reiners C.A., Hentz J.G., Muenter M.D. Motor unit changes in sporadic idiopathic Parkinson&#x2019;s disease. Mov. Disord. 2000;15:238&#x2013;243. doi: 10.1002/1531-8257(200003)15:2&lt;238::AID-MDS1006&gt;3.0.CO;2-J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8257(200003)15:2&lt;238::AID-MDS1006&gt;3.0.CO;2-J</ArticleId><ArticleId IdType="pubmed">10752572</ArticleId></ArticleIdList></Reference><Reference><Citation>Caviness J., Smith B., Stevens J.C., Adler C., Caselli R., Hentz J., Manfred M., Muenter D. Motor unit number estimates in idiopathic Parkinson&#x2019;s disease. Parkinsonism Relat. Disord. 2002;8:161&#x2013;164. doi: 10.1016/S1353-8020(01)00007-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1353-8020(01)00007-4</ArticleId><ArticleId IdType="pubmed">12039425</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivacqua G., Biagioni F., Yu S., Casini A., Bucci D., D&#x2019;Este L., Fornai F. Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice. J. Chem. Neuroanat. 2012;44:76&#x2013;85. doi: 10.1016/j.jchemneu.2012.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2012.04.003</ArticleId><ArticleId IdType="pubmed">22580273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendritzki S., Schmidt S., Sczepan T., Zhu X.-R., Segelcke D., L&#xfc;bbert H. Spinal cord pathology in alpha-synuclein transgenic mice. Parkinson&#x2019;s Dis. 2010;2010:375462. doi: 10.4061/2010/375462.</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2010/375462</ArticleId><ArticleId IdType="pmc">PMC2957200</ArticleId><ArticleId IdType="pubmed">20976083</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007;10:615&#x2013;622. doi: 10.1038/nn1876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1876</ArticleId><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Shults C.W., Rockenstein E., Crews L., Adame A., Mante M., Larrea G., Hashimoto M., Song D., Iwatsubo T., Tsuboi K. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human &#x3b1;-synuclein under oligodendrocyte promoter: Implications for multiple system atrophy. J. Neurosci. 2005;25:10689&#x2013;10699. doi: 10.1523/JNEUROSCI.3527-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3527-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725840</ArticleId><ArticleId IdType="pubmed">16291942</ArticleId></ArticleIdList></Reference><Reference><Citation>Acsadi G., Li X., Murphy K.J., Swoboda K.J., Parker G.C. Alpha-synuclein loss in spinal muscular atrophy. J. Mol. Neurosci. 2011;43:275&#x2013;283. doi: 10.1007/s12031-010-9422-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9422-1</ArticleId><ArticleId IdType="pmc">PMC3918138</ArticleId><ArticleId IdType="pubmed">20640532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline R.A., Kaifer K.A., Osman E.Y., Carella F., Tiberi A., Ross J., Pennetta G., Lorson C.L., Murray L.M. Comparison of independent screens on differentially vulnerable motor neurons reveals alpha-synuclein as a common modifier in motor neuron diseases. PLoS Genet. 2017;13:e1006680. doi: 10.1371/journal.pgen.1006680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1006680</ArticleId><ArticleId IdType="pmc">PMC5391970</ArticleId><ArticleId IdType="pubmed">28362802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak S. Pain in amyotrophic lateral sclerosis: A narrative review. J. Yeungnam Med. Sci. 2022;39:181&#x2013;189. doi: 10.12701/jyms.2022.00332.</Citation><ArticleIdList><ArticleId IdType="doi">10.12701/jyms.2022.00332</ArticleId><ArticleId IdType="pmc">PMC9273136</ArticleId><ArticleId IdType="pubmed">35673830</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurwitz N., Radakovic R., Boyce E., Peryer G. Prevalence of pain in amyotrophic lateral sclerosis: A systematic review and meta-analysis. Amyotroph. Lateral Scler. Front. Degener. 2021;22:449&#x2013;458. doi: 10.1080/21678421.2021.1892765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1892765</ArticleId><ArticleId IdType="pubmed">33661072</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack R.S., Joyce N., Carter G.T., Paganoni S., Karam C. Complementary and alternative therapies in amyotrophic lateral sclerosis. Neurol. Clin. 2015;33:909&#x2013;936. doi: 10.1016/j.ncl.2015.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.008</ArticleId><ArticleId IdType="pmc">PMC4712627</ArticleId><ArticleId IdType="pubmed">26515629</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalbello-Haas V., Florence J.M., Krivickas L.S. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst. Rev. 2014;5:2013. doi: 10.1002/14651858.CD005229.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005229.pub2</ArticleId><ArticleId IdType="pubmed">18425913</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J.C., Preux P.M., Magy L., Boirie Y., Vallat J.M., Beaufrere B., Couratier P. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am. J. Clin. Nutr. 2001;74:328&#x2013;334. doi: 10.1093/ajcn/74.3.328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/74.3.328</ArticleId><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Aridegbe T., Kandler R., Walters S.J., Walsh T., Shaw P.J., McDermott C.J. The natural history of motor neuron disease: Assessing the impact of specialist care. Amyotroph. Lateral Scler. Front. Degener. 2013;14:13&#x2013;19. doi: 10.3109/17482968.2012.690419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.690419</ArticleId><ArticleId IdType="pubmed">22642305</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Jackson C.E., Kasarskis E.J., England J.D., Forshew D., Johnston W., Kalra S., Katz J.S., Mitsumoto H., Rosenfeld J., et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1227&#x2013;1233. doi: 10.1212/WNL.0b013e3181bc01a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc01a4</ArticleId><ArticleId IdType="pmc">PMC2764728</ArticleId><ArticleId IdType="pubmed">19822873</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst H.J., Mack K.L., Brown D.G., Brandon N.J., Shorter J. The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future. Med. Res. Rev. 2020;40:1352&#x2013;1384. doi: 10.1002/med.21661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21661</ArticleId><ArticleId IdType="pmc">PMC7417284</ArticleId><ArticleId IdType="pubmed">32043626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellingham M.C. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: What have we learned in the last decade? CNS Neurosci. Ther. 2011;17:4&#x2013;31. doi: 10.1111/j.1755-5949.2009.00116.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2009.00116.x</ArticleId><ArticleId IdType="pmc">PMC6493865</ArticleId><ArticleId IdType="pubmed">20236142</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D. Edaravone: A new drug approved for ALS. Cell. 2017;171:725. doi: 10.1016/j.cell.2017.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.011</ArticleId><ArticleId IdType="pubmed">29100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K., Itoyama Y., Sobue G., Tsuji S., Aoki M., Doyu M., Hamada C., Kondo K., Yoneoka T., Akimoto M., et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph. Lateral. Scler. Front. Degener. 2014;15:610&#x2013;617. doi: 10.3109/21678421.2014.959024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin. Pharm. 2017;18:735&#x2013;738. doi: 10.1080/14656566.2017.1319937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2017.1319937</ArticleId><ArticleId IdType="pubmed">28406335</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomar S., Gupta S., Singal A., Soni R. Efficacy and safety of edaravone in amyotrophic lateral sclerosis patients in Indian population. J. Assoc. Physicians India. 2022;70:11&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">35443425</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.-M., Park D., Kim H.-J., Park J.-S. Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study. BMC Neurol. 2022;22:260. doi: 10.1186/s12883-022-02788-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-022-02788-x</ArticleId><ArticleId IdType="pmc">PMC9281019</ArticleId><ArticleId IdType="pubmed">35836136</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S., Duguez S., Duddy W. Personalized medicine and molecular interaction networks in amyotrophic lateral sclerosis (ALS): Current knowledge. J. Pers. Med. 2018;8:44. doi: 10.3390/jpm8040044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm8040044</ArticleId><ArticleId IdType="pmc">PMC6313785</ArticleId><ArticleId IdType="pubmed">30551677</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly C.V., Miller T.M. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2018;31:648&#x2013;654. doi: 10.1097/WCO.0000000000000594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000594</ArticleId><ArticleId IdType="pmc">PMC7291817</ArticleId><ArticleId IdType="pubmed">30028737</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C.F., Swayze E.E. RNA targeting therapeutics: Molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 2010;50:259&#x2013;293. doi: 10.1146/annurev.pharmtox.010909.105654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.010909.105654</ArticleId><ArticleId IdType="pubmed">20055705</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N., Nishiyama A., Warita H., Aoki M. Genetics of amyotrophic lateral sclerosis: Seeking therapeutic targets in the era of gene therapy. J. Hum. Genet. 2022 doi: 10.1038/s10038-022-01055-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s10038-022-01055-8</ArticleId><ArticleId IdType="pubmed">35691950</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Arai K., Del Tredici K., Toledo J.B., Robinson J.L., Lee E.B., Kuwabara S., Shibuya K., Irwin D.J., Fang L. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 2014;128:423&#x2013;437. doi: 10.1007/s00401-014-1299-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1299-6</ArticleId><ArticleId IdType="pmc">PMC4384652</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojaimi Y.A., Dangoumau A., Alarcan H., Hergesheimer R., Vourc&#x2019;h P., Corcia P., Lanznaster D., Blasco H. TAR DNA-binding protein of 43 kDa (TDP-43) and amyotrophic lateral sclerosis (ALS): A promising therapeutic target. Expert Opin. Ther. Targets. 2022;26:575&#x2013;592. doi: 10.1080/14728222.2022.2083958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2022.2083958</ArticleId><ArticleId IdType="pubmed">35652285</ArticleId></ArticleIdList></Reference><Reference><Citation>De Boer E.M.J., Orie V.K., Williams T., Baker M.R., De Oliveira H.M., Polvikoski T., Silsby M., Menon P., van den Bos M., Halliday G.M. TDP-43 proteinopathies: A new wave of neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry. 2021;92:86&#x2013;95. doi: 10.1136/jnnp-2020-322983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322983</ArticleId><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M., Cleveland D.W. Biological spectrum of amyotrophic lateral sclerosis prions. Cold Spring Harb. Perspect. Med. 2017;7:a024133. doi: 10.1101/cshperspect.a024133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024133</ArticleId><ArticleId IdType="pmc">PMC5666626</ArticleId><ArticleId IdType="pubmed">28062558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D., Hatano M., Suzuki N. RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration. Sci. Transl. Med. 2017;9:eaah5436. doi: 10.1126/scitranslmed.aah5436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aah5436</ArticleId><ArticleId IdType="pubmed">29118263</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker L.A., Huang B., Bieri G., Ma R., Knowles D.A., Jafar-Nejad P., Messing J., Kim H.J., Soriano A., Auburger G. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Y.M., De Conti L., Avenda&#xf1;o-V&#xe1;zquez S.E., Dhir A., Romano M., D&#x2019;ambrogio A., Tollervey J., Ule J., Baralle M., Buratti E. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30:277&#x2013;288. doi: 10.1038/emboj.2010.310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.310</ArticleId><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P., Sivakumar P., Humphrey J., Lo K., Ricketts T., Oliveira H., Brito-Armas J.M., Kalmar B., Ule A., Yu Y. Mice with endogenous TDP-43 mutations exhibit gain of splicing function and characteristics of amyotrophic lateral sclerosis. EMBO J. 2018;37:e98684. doi: 10.15252/embj.201798684.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201798684</ArticleId><ArticleId IdType="pmc">PMC5983119</ArticleId><ArticleId IdType="pubmed">29764981</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyama A., Sugai A., Kato T., Ishihara T., Shiga A., Toyoshima Y., Koyama M., Konno T., Hirokawa S., Yokoseki A., et al. Increased cytoplasmic TARDBP mRNA in affected spinal motor neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Res. 2016;44:5820&#x2013;5836. doi: 10.1093/nar/gkw499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw499</ArticleId><ArticleId IdType="pmc">PMC4937342</ArticleId><ArticleId IdType="pubmed">27257061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C.F., Kordasiewicz H.B., Cleveland D.W. Antisense drugs make sense for neurological diseases. Annu. Rev. Pharmacol. Toxicol. 2021;61:831&#x2013;852. doi: 10.1146/annurev-pharmtox-010919-023738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-010919-023738</ArticleId><ArticleId IdType="pmc">PMC8682074</ArticleId><ArticleId IdType="pubmed">33035446</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim J.R., Williams L.A., Limone F., Guerra San Juan I., Davis-Dusenbery B.N., Mordes D.A., Burberry A., Steinbaugh M.J., Gamage K.K., Kirchner R., et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 2019;22:167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z.E., L&#xf3;pez-Erauskin J., Baughn M.W., Zhang O., Drenner K., Sun Y., Freyermuth F., McMahon M.A., Beccari M.S., Artates J.W. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 2019;22:180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Krus K.L., Strickland A., Yamada Y., Devault L., Schmidt R.E., Bloom A.J., Milbrandt J., DiAntonio A. Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy. Cell Rep. 2022;39 doi: 10.1016/j.celrep.2022.111001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111001</ArticleId><ArticleId IdType="pmc">PMC9327139</ArticleId><ArticleId IdType="pubmed">35767949</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim J.R., Pintacuda G., Nash L.A., San Juan I.G., Eggan K. Connecting TDP-43 pathology with neuropathy. Trends Neurosci. 2021;44:424&#x2013;440. doi: 10.1016/j.tins.2021.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2021.02.008</ArticleId><ArticleId IdType="pubmed">33832769</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden A.C., Kim H.-J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon K., Ross J.P., Bertone V., Gobbo M., Anoja N., Karamchandani J., Dion P.A., Rouleau G.A., Genge A. The value of testing for ATXN2 intermediate repeat expansions in routine clinical practice for amyotrophic lateral sclerosis. Eur. J. Hum. Genet. 2022 doi: 10.1038/s41431-022-01146-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-022-01146-2</ArticleId><ArticleId IdType="pubmed">35864146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Lyashchenko A.K., Lu L., Nasrabady S.E., Elmaleh M., Mendelsohn M., Nemes A., Tapia J.C., Mentis G.Z., Shneider N.A. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat. Commun. 2016;7:10465. doi: 10.1038/ncomms10465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10465</ArticleId><ArticleId IdType="pmc">PMC4742863</ArticleId><ArticleId IdType="pubmed">26842965</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov V.A., Lyashchenko A.K., Blanco-Redondo B., Jafar-Nejad P., Shneider N.A. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med. 2022;28:104&#x2013;116. doi: 10.1038/s41591-021-01615-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01615-z</ArticleId><ArticleId IdType="pmc">PMC8799464</ArticleId><ArticleId IdType="pubmed">35075293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Baughn M., Rigo F., Sun S., Liu P., Li H.-R., Jiang J., Watt A.T., Chun S., Katz M. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. USA. 2013;110:E4530&#x2013;E4539. doi: 10.1073/pnas.1318835110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly C.J., Zhang P.-W., Pham J.T., Haeusler A.R., Mistry N.A., Vidensky S., Daley E.L., Poth E.M., Hoover B., Fines D.M. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis. 2022.  [(accessed on 9 July 2022)].  Available online:  https://investors.biogen.com/news-releases/news-release-details/biogen-and-ionis-announce-topline-phase-1-study-results.</Citation></Reference><Reference><Citation>Tran H., Moazami M.P., Yang H., McKenna-Yasek D., Douthwright C.L., Pinto C., Metterville J., Shin M., Sanil N., Dooley C., et al. Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide. Nat. Med. 2022;28:117&#x2013;124. doi: 10.1038/s41591-021-01557-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01557-6</ArticleId><ArticleId IdType="pmc">PMC8861976</ArticleId><ArticleId IdType="pubmed">34949835</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V., Valdmanis P.N., Gould P.V., Julien J.P., Dupre N. From animal models to human disease: A genetic approach for personalized medicine in ALS. Acta Neuropathol. Commun. 2016;4:70. doi: 10.1186/s40478-016-0340-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0340-5</ArticleId><ArticleId IdType="pmc">PMC4940869</ArticleId><ArticleId IdType="pubmed">27400686</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C., Genge A., Glass J., Ladha S., Ludolph A.L., et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Cudkowicz M.E., Shaw P.J., Graham D., Fradette S., Houshyar H., Bennett F., Lane R.M., Nestorov I., Fanning L. Safety, PK, PD, and exploratory efficacy in a single and multiple-dose study of a SOD1 antisense oligonucleotide (BIIB067) administered to participants with ALS; Proceedings of the American Academy of Neruology 2019&#x2014;71st Annual Meeting; Philadelphia, PA, USA. 4&#x2013;10 May 2019.</Citation></Reference><Reference><Citation>Miller T.M., Cudkowicz M.E. Results from the Phase 3 VALOR study and its open-label extension: Evaluating the clinical efficacy and safety of Tofersen in adults with ALS and confirmed SOD1 mutation; Proceedings of the American Neurological Association Annual Meeting; Virtual. 17&#x2013;19 October 2021.</Citation></Reference><Reference><Citation>Flynn L.L., Li R., Pitout I.L., Aung-Htut M.T., Larcher L.M., Cooper J.A.L., Greer K.L., Hubbard A., Griffiths L., Bond C.S., et al. Single stranded fully modified-phosphorothioate oligonucleotides can induce structured nuclear inclusions, alter nuclear protein localization and disturb the transcriptome in vitro. Front. Genet. 2022;13:Art-791416. doi: 10.3389/fgene.2022.791416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.791416</ArticleId><ArticleId IdType="pmc">PMC9019733</ArticleId><ArticleId IdType="pubmed">35464859</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P., Dave K.D., Kordower J.H. Therapeutic approaches to target alpha-synuclein pathology. Exp. Neurol. 2017;298:225&#x2013;235. doi: 10.1016/j.expneurol.2017.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2017.10.003</ArticleId><ArticleId IdType="pmc">PMC6541231</ArticleId><ArticleId IdType="pubmed">28987463</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao X., Ou M.T., Karuppagounder S.S., Kam T.-I., Yin X., Xiong Y., Ge P., Umanah G.E., Brahmachari S., Shin J.-H. Pathological &#x3b1;-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016;353:aah3374. doi: 10.1126/science.aah3374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aah3374</ArticleId><ArticleId IdType="pmc">PMC5510615</ArticleId><ArticleId IdType="pubmed">27708076</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastava A.N., Redeker V., Fritz N., Pieri L., Almeida L.G., Spolidoro M., Liebmann T., Bousset L., Renner M., L&#xe9;na C. &#x3b1;-synuclein assemblies sequester neuronal &#x3b1;3-Na+/K+-ATP ase and impair Na+ gradient. EMBO J. 2015;34:2408&#x2013;2423. doi: 10.15252/embj.201591397.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201591397</ArticleId><ArticleId IdType="pmc">PMC4601662</ArticleId><ArticleId IdType="pubmed">26323479</ArticleId></ArticleIdList></Reference><Reference><Citation>Brys M., Ellenbogen A., Fanning L., Penner N., Yang M., Welch M., Koenig E., David E., Fox T., Makh S. Randomized, double-blind, placebo-controlled, single ascending dose study of anti-&#x3b1;-synuclein antibody BIIB054 in patients with Parkinson&#x2019;s disease. Neurology. 2018;90:1154&#x2013;1163. doi: 10.1002/mds.27738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27738</ArticleId></ArticleIdList></Reference><Reference><Citation>Arotcarena M.-L., Teil M., Dehay B. Autophagy in synucleinopathy: The overwhelmed and defective machinery. Cells. 2019;8:565. doi: 10.3390/cells8060565.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8060565</ArticleId><ArticleId IdType="pmc">PMC6627933</ArticleId><ArticleId IdType="pubmed">31181865</ArticleId></ArticleIdList></Reference><Reference><Citation>Moors T.E., Hoozemans J.J., Ingrassia A., Beccari T., Parnetti L., Chartier-Harlin M.-C., Van De Berg W.D. Therapeutic potential of autophagy-enhancing agents in Parkinson&#x2019;s disease. Mol. Neurodegener. 2017;12:11. doi: 10.1186/s13024-017-0154-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0154-3</ArticleId><ArticleId IdType="pmc">PMC5267440</ArticleId><ArticleId IdType="pubmed">28122627</ArticleId></ArticleIdList></Reference><Reference><Citation>Migdalska-Richards A., Schapira A.H. The relationship between glucocerebrosidase mutations and Parkinson disease. J. Neurochem. 2016;139:77&#x2013;90. doi: 10.1111/jnc.13385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13385</ArticleId><ArticleId IdType="pmc">PMC5111601</ArticleId><ArticleId IdType="pubmed">26860875</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy K.E., Gysbers A.M., Abbott S.K., Tayebi N., Kim W.S., Sidransky E., Cooper A., Garner B., Halliday G.M. Reduced glucocerebrosidase is associated with increased &#x3b1;-synuclein in sporadic Parkinson&#x2019;s disease. Brain. 2014;137:834&#x2013;848. doi: 10.1093/brain/awt367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt367</ArticleId><ArticleId IdType="pmc">PMC3927701</ArticleId><ArticleId IdType="pubmed">24477431</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnetti L., Paciotti S., Eusebi P., Dardis A., Zampieri S., Chiasserini D., Tasegian A., Tambasco N., Bembi B., Calabresi P. Cerebrospinal fluid &#x3b2;-glucocerebrosidase activity is reduced in Parkinson&#x2019;s disease patients. Mov. Disord. 2017;32:1423&#x2013;1431. doi: 10.1002/mds.27136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27136</ArticleId><ArticleId IdType="pubmed">28843015</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardi S.P., Cheng S.H., Shihabuddin L.S. Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle. Prog. Neurobiol. 2015;125:47&#x2013;62. doi: 10.1016/j.pneurobio.2014.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2014.12.001</ArticleId><ArticleId IdType="pubmed">25573151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullin S., Smith L., Lee K., D&#x2019;Souza G., Woodgate P., Elflein J., H&#xe4;llqvist J., Toffoli M., Streeter A., Hosking J. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: A nonrandomized, noncontrolled trial. JAMA Neuorol. 2020;77:427&#x2013;434. doi: 10.1001/jamaneurol.2019.4611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4611</ArticleId><ArticleId IdType="pmc">PMC6990847</ArticleId><ArticleId IdType="pubmed">31930374</ArticleId></ArticleIdList></Reference><Reference><Citation>Price D.L., Koike M.A., Khan A., Wrasidlo W., Rockenstein E., Masliah E., Bonhaus D. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson&#x2019;s disease. Sci. Rep. 2018;8:16165. doi: 10.1038/s41598-018-34490-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-34490-9</ArticleId><ArticleId IdType="pmc">PMC6212487</ArticleId><ArticleId IdType="pubmed">30385782</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan R., Tsubery H., Proschitsky M.Y., Asp E., Lulu M., Gilead S., Gartner M., Waltho J.P., Davis P.J., Hounslow A.M. A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies. J. Mol. Biol. 2014;426:2500&#x2013;2519. doi: 10.1016/j.jmb.2014.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2014.04.015</ArticleId><ArticleId IdType="pubmed">24768993</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Yuan Y., Li Y., Han D., Liu T., Yang N., Mi X., Hong J., Liu K., Song Y. Inhibition of &#x3b1;-synuclein accumulation improves neuronal apoptosis and delayed postoperative cognitive recovery in aged mice. Oxid. Med. Cell. Longev. 2021;2021:5572899. doi: 10.1155/2021/5572899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5572899</ArticleId><ArticleId IdType="pmc">PMC8181110</ArticleId><ArticleId IdType="pubmed">34194605</ArticleId></ArticleIdList></Reference><Reference><Citation>Somayaji M., Lanseur Z., Choi S.J., Sulzer D., Mosharov E.V. Roles for &#x3b1;-synuclein in gene expression. Genes. 2021;12:1166. doi: 10.3390/genes12081166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12081166</ArticleId><ArticleId IdType="pmc">PMC8393936</ArticleId><ArticleId IdType="pubmed">34440340</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Wang G., Wang Z., Wang G., Huang J., Liu B. Repurposing small-molecule drugs for modulating toxic protein aggregates in neurodegenerative diseases. Drug Discov. 2022;27:1994&#x2013;2007. doi: 10.1016/j.drudis.2022.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2022.04.003</ArticleId><ArticleId IdType="pubmed">35395400</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n-Ar&#xed;s D., Pavia-Collado R., Miquel-Rio L., Coppola-Segovia V., Ferr&#xe9;s-Coy A., Ruiz-Bronchal E., Galofr&#xe9; M., Paz V., Campa L., Revilla R. Anti-&#x3b1;-synuclein ASO delivered to monoamine neurons prevents &#x3b1;-synuclein accumulation in a Parkinson&#x2019;s disease-like mouse model and in monkeys. EBioMedicine. 2020;59:102944. doi: 10.1016/j.ebiom.2020.102944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102944</ArticleId><ArticleId IdType="pmc">PMC7452525</ArticleId><ArticleId IdType="pubmed">32810825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole T.A., Zhao H., Collier T.J., Sandoval I., Sortwell C.E., Steece-Collier K., Daley B.F., Booms A., Lipton J., Welch M., et al. &#x3b1;-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson&#x2019;s disease. JCI Insight. 2021;6:e135633. doi: 10.1172/jci.insight.135633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.135633</ArticleId><ArticleId IdType="pmc">PMC8021121</ArticleId><ArticleId IdType="pubmed">33682798</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutros S.W., Raber J., Unni V.K. Effects of alpha-synuclein targeted antisense oligonucleotides on Lewy body-like pathology and behavioral disturbances induced by injections of pre-formed fibrils in the mouse motor cortex. J. Parkinson&#x2019;s Dis. 2021;11:1091. doi: 10.3233/JPD-212566.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-212566</ArticleId><ArticleId IdType="pmc">PMC8461707</ArticleId><ArticleId IdType="pubmed">34057097</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Turner M.R., Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2019;20:303&#x2013;309. doi: 10.1080/21678421.2019.1587634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587634</ArticleId><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>